Gemcitabine pharmacogenomics: Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1951-1959

  Kocabas, Neslihan Aygun ^a,c   Aksoy, Pinar ^a,d   Pelleymounter, Linda L ^a   Moon, Irene ^a   Ryu, Jeong Seon ^a,e,f   Gilbert, Judith A ^a   Salavaggione, Oreste Ezequel ^a   Eckloff, Bruce W ^a   Wieben, Eric D ^a   Yee, Vivien ^b   Weinshilboum, Richard M ^a   Ames, Matthew M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GAZI UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e Inha University Hospital   (South Korea)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOENZYME; CYTIDYLATE KINASE; DEOXYCYTIDINE KINASE; GEMCITABINE; PHOSPHOTRANSFERASE; SERINE; UNCLASSIFIED DRUG; VALINE;

AFRICAN AMERICAN; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; ASIAN AMERICAN; CELL STRAIN COS1; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; EUROPEAN AMERICAN; FUNCTIONAL GENOMICS; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HISPANIC; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RETICULOCYTE LYSATE; SEQUENCE ANALYSIS; WILD TYPE;

ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; HAPLOTYPES; HUMANS; KINETICS; LINKAGE DISEQUILIBRIUM; MODELS, MOLECULAR; NUCLEOSIDE-PHOSPHATE KINASE; PHARMACOGENETICS;

ORYCTOLAGUS CUNICULUS;

EID: 50049105739     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020925     Document Type: Article

References (38)

1. Bergman AM, Pinedo HM, Jongsma AP, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, and Peters GJ (1999) Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57:397-406.
2. Bucurenci N, Sakamoto H, Briozzo P, Palibroda N, Serina L, Sarfati RS, Labesse G, Briand G, Danchin A, Bǎrzu O, et al. (1996) CMP kinase from Escherichia coli is structurally related to other nucleoside monophosphate kinases. J Biol Chem 271:2856-2862.
3. Carmichael J (1998) The role of gemcitabine in the treatment of other tumours. Br J Cancer 78 (Suppl 3):21-25.
4. Cheng YC (2001) Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. Cancer Lett 162 (Suppl):S33-S37.
5. Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W, Seeber S, and Schütte J (1994) Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 8:780-785.
6. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, and Dumontet C (2004) Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 4:8.
7. Galmarini CM, Mackey JR, and Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875-890.
8. Galmarini CM, Mackey JR, and Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415-424.
9. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, and Danesi R (2006) Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5:1387-1395.
10. Hartl DL and Clark AG (2000) Organization of Genetic Variation. Sinauer Associates, Sunderland, MA.
11. Hendrick P (2000) Genetics of Populations. Jones and Bartlett Publishers, Sudbury, MA.
12. Hsu CH, Liou JY, Dutschman GE, and Cheng YC (2005) Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium. Mol Pharmacol 67:806-814.
13. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, and Schellens JH (2006) Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 62:681-684.
14. Jones TA, Zou J-Y, Cowan SW, and Kjeldgaard M (1991) Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
15. Kozak M (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283-292.
16. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:946-950.
17. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, and Peters GJ (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1:371-376.
18. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, and Ribeiro R (2007) Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 323:935-945.
19. Liou JY, Dutschman GE, Lam W, Jiang Z, and Cheng YC (2002) Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 62:1624-1631.
20. Loots GG, Ovcharenko I, Pachter L, Dubchak I, and Rubin EM (2002) rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res 12:832-839.
21. Maring JG, Groen HJ, Wachters FM, Uges DR, and de Vries EG (2005) Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5:226-243.
22. Merritt EA and Bacon DJ (1997) Raster3D: photorealistic molecular graphics. Methods Enzymol: 505-524.
23. Mini E, Nobili S, Caciagli B, Landini I, and Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5):v7-v12.
24. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, and Kohgo Y (2007) Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96:457-463.
25. Owens JK, Shewach DS, Ullman B, and Mitchell BS (1992) Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 52:2389-2393.
26. Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Kamphuis JA, De Pooter CM, Peters GJ, Lardon F, and Vermorken JB (2006) The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer 6:142.
27. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, and Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10.
28. Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, and Peters GJ (1994) Schedule dependence of sensitivity to 2′,2′- difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48:1327-1339.
29. Sabini E, Ort S, Monnerjahn C, Konrad M, and Lavie A (2003) Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 19:513-519.
30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, and Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425-434.
31. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, and Iacobuzio-Donahue CA (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. [Erratum in: Clin Cancer Res 2007 13:4313]. Clin Cancer Res 12:2492-2497.
32. Segura-Peña D, Sekulic N, Ort S, Konrad M, and Lavie A (2004) Substrate-induced conformational changes in human UMP/CMP kinase. J Biol Chem 279:33882-33889.
33. Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, and Landegent JE (1995) In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol 71:41-47.
34. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123:585-595.
35. Ulrich CM, Robien K, and McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3:912-920.
36. Usova EV and Eriksson S (2002) Identification of residues involved in the substrate specificity of human and murine dCK. Biochem Pharmacol 64:1559-1567.
37. Van Rompay AR, Johansson M, and Karlsson A (1999) Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. Mol Pharmacol 56:562-569.
38. Wang L, Sullivan W, Toft D, and Weinshilboum R (2003) Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 13:555-564.